SCHEMBL13340328

SCHEMBL13340328

Cc1cccc(C(=O)Nc2cccc(CNc3cncc(Cl)n3)c2)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 9/20 0.65
RET P07949 1/20 0.65
PDGFRB P09619 1/20 0.65
KIT P10721 1/20 0.65
SRC P12931 1/20 0.65
PDGFRA P16234 1/20 0.65
FLT1 P17948 1/20 0.65
FLT4 P35916 1/20 0.65
KDR P35968 1/20 0.65
FRK P42685 1/20 0.65
DDR1 Q08345 1/20 0.65
SIRT2 Q8IXJ6 1/20 0.52
SIRT1 Q96EB6 1/20 0.52
SIRT3 Q9NTG7 1/20 0.52
KCNK3 O14649 7/20 0.52
KCNK9 Q9NPC2 6/20 0.52
KCNH2 Q12809 1/20 0.52
AURKA O14965 1/20 0.51
AURKB Q96GD4 1/20 0.51
KMT2A Q03164 3/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13340335 0.92 CSF1R (0.65) CSF1RRETPDGFRBKITSRC
SCHEMBL4323640 0.90 CSF1R (0.66) CSF1RRETPDGFRBKITSRC
SCHEMBL13340329 0.85 CSF1R (0.66) CSF1RDDR1KCNK3KCNK9AURKA
SCHEMBL4314543 0.83 BRAF (0.52) CSF1RRETPDGFRBKITSRC
SCHEMBL2064858 0.82 CSF1R (0.67) CSF1RRETPDGFRBKITSRC
SCHEMBL4324513 0.82 CSF1R (0.66) CSF1RRETPDGFRBKITSRC
SCHEMBL13340119 0.80 CSF1R (0.55) CSF1RRETPDGFRBKITSRC
SCHEMBL17954627 0.79 BRAF (0.43) CSF1RRETPDGFRBKITSRC
SCHEMBL13340375 0.79 CSF1R (1.00) CSF1RRETPDGFRBKITSRC
SCHEMBL3474628 0.79 CSF1R (1.00) CSF1RRETPDGFRBKITSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2848610-B1 Inhibitors of kinase activity YM BIOSCIENCES AUSTRALIA PTY (AU) 2017-10-11 EP disclosed
US-9029386-B2 Pyridine derivatives useful as kinase inhibitors GILEAD SCIENCES, INC. (US) 2015-05-12 US disclosed
US-8461161-B2 Substituted pyrazines as inhibitors of kinase activity YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2013-06-11 US disclosed
US-8461161-B2 Substituted pyrazines as inhibitors of kinase activity YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2013-06-11 US disclosed
US-20130137660-A1 INHIBITORS OF KINASE ACTIVITY YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2013-05-30 US disclosed
US-20100130447-A1 INHIBITORS OF KINASE ACTIVITY YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2010-05-27 US disclosed
US-20100130447-A1 INHIBITORS OF KINASE ACTIVITY YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2010-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130137660-A1 INHIBITORS OF KINASE ACTIVITY FRK, LCK, FLT3 CSF1R 62/4885RET 4/4885PDGFRB 97/4885
US-20100130447-A1 INHIBITORS OF KINASE ACTIVITY FRK, LCK, FLT3 CSF1R 62/4885RET 4/4885PDGFRB 97/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.